These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
58 related items for PubMed ID: 11452450
1. [Target molecules of anti-tumor drugs and cell checkpoints]. Sugimoto K. Rinsho Ketsueki; 2001 May; 42(5):356-8. PubMed ID: 11452450 [No Abstract] [Full Text] [Related]
2. Cell-cycle control in the face of damage--a matter of life or death. Clarke PR, Allan LA. Trends Cell Biol; 2009 Mar; 19(3):89-98. PubMed ID: 19168356 [Abstract] [Full Text] [Related]
3. The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs. Potter AJ, Rabinovitch PS. Mutat Res; 2005 May 02; 572(1-2):27-44. PubMed ID: 15790488 [Abstract] [Full Text] [Related]
4. Mechanistic pathways of antioxidant cytoprotection by a novel IH636 grape seed proanthocyanidin extract. Bagchi D, Ray SD, Bagchi M, Preuss HG, Stohs SJ. Indian J Exp Biol; 2002 Jun 02; 40(6):717-26. PubMed ID: 12587719 [Abstract] [Full Text] [Related]
5. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Swift LP, Cutts SM, Nudelman A, Levovich I, Rephaeli A, Phillips DR. Cancer Chemother Pharmacol; 2008 Apr 02; 61(5):739-49. PubMed ID: 17594094 [Abstract] [Full Text] [Related]
6. The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels. Ruiz de Almodóvar C, Ruiz-Ruiz C, Muñoz-Pinedo C, Robledo G, López-Rivas A. Oncogene; 2001 Oct 25; 20(48):7128-33. PubMed ID: 11704839 [Abstract] [Full Text] [Related]
7. New method for the detection of reactive oxygen species in anti-tumoural activity of adriamycin: a comparison between hypoxic and normoxic cells. Rharass T, Vigo J, Salmon JM, Ribou AC. Free Radic Res; 2008 Feb 25; 42(2):124-34. PubMed ID: 18297605 [Abstract] [Full Text] [Related]
8. UVC inhibits HIF-1alpha protein translation by a DNA damage- and topoisomerase I-independent pathway. Rapisarda A, Melillo G. Oncogene; 2007 Oct 18; 26(48):6875-84. PubMed ID: 17496931 [Abstract] [Full Text] [Related]
9. DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment. Skladanowski A, Bozko P, Sabisz M. Chem Rev; 2009 Jul 18; 109(7):2951-73. PubMed ID: 19522503 [No Abstract] [Full Text] [Related]
10. Ionizing radiation but not anticancer drugs causes cell cycle arrest and failure to activate the mitochondrial death pathway in MCF-7 breast carcinoma cells. Jänicke RU, Engels IH, Dunkern T, Kaina B, Schulze-Osthoff K, Porter AG. Oncogene; 2001 Aug 16; 20(36):5043-53. PubMed ID: 11526489 [Abstract] [Full Text] [Related]
11. Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation. Koceva-Chyła A, Jedrzejczak M, Skierski J, Kania K, Jóźwiak Z. Apoptosis; 2005 Dec 16; 10(6):1497-514. PubMed ID: 16215684 [Abstract] [Full Text] [Related]
12. From DNA damage to G2 arrest: the many roles of topoisomerase II. Larsen AK, Escargueil AE, Skladanowski A. Prog Cell Cycle Res; 2003 Dec 16; 5():295-300. PubMed ID: 14593724 [Abstract] [Full Text] [Related]
13. Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response. Gatti L, Supino R, Perego P, Pavesi R, Caserini C, Carenini N, Righetti SC, Zuco V, Zunino F. Cell Death Differ; 2002 Dec 16; 9(12):1352-9. PubMed ID: 12478472 [Abstract] [Full Text] [Related]
14. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM. Cancer Res; 2006 May 01; 66(9):4863-71. PubMed ID: 16651442 [Abstract] [Full Text] [Related]
15. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Verheul HM, Qian DZ, Carducci MA, Pili R. Cancer Chemother Pharmacol; 2007 Aug 01; 60(3):329-39. PubMed ID: 17256134 [Abstract] [Full Text] [Related]
16. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Liu X, Yue P, Khuri FR, Sun SY. Cancer Res; 2005 Oct 15; 65(20):9169-75. PubMed ID: 16230375 [Abstract] [Full Text] [Related]
17. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Baptiste N, Friedlander P, Chen X, Prives C. Oncogene; 2002 Jan 03; 21(1):9-21. PubMed ID: 11791172 [Abstract] [Full Text] [Related]
18. 123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, beta-, or gamma-radiation-resistant cell lines. Reske SN, Deisenhofer S, Glatting G, Zlatopolskiy BD, Morgenroth A, Vogg AT, Buck AK, Friesen C. J Nucl Med; 2007 Jun 03; 48(6):1000-7. PubMed ID: 17504875 [Abstract] [Full Text] [Related]
19. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Mizutani H, Tada-Oikawa S, Hiraku Y, Kojima M, Kawanishi S. Life Sci; 2005 Feb 11; 76(13):1439-53. PubMed ID: 15680309 [Abstract] [Full Text] [Related]
20. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers. Hsiao CJ, Li TK, Chan YL, Hsin LW, Liao CH, Lee CH, Lyu PC, Guh JH. Biochem Pharmacol; 2008 Feb 15; 75(4):847-56. PubMed ID: 18035333 [Abstract] [Full Text] [Related] Page: [Next] [New Search]